Vasculitis & polymyalgia rheumatica
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry
Authors' conclusion
In this large US-based study of patients with PMR receiving rheumatology care, only a minority of patients were prescribed steroid-sparing agents during the first 24 months of follow-up; most patients remained on glucocorticoids past one year.
Study context
- Population
- Patients with PMR receiving care from rheumatology providers in the ACR RISE registry, 2016 to 2022; main analysis in patients new to rheumatology practices16,703 new patients analysed
- Participants
- 26,102 patients
- Outcome
- Treatment patterns in new patients
Methodological detailsnational registry (ACR RISE), multivariate logistic regression
- National registry (ACR RISE)
- Multivariate logistic regression
Main finding
As reported in the abstract
On GC at baseline
92.3%
On steroid-sparing agent at baseline
13.1%
Remained on GC at 12 to 24 months
63.8%
Prescribed antirheumatic medications through follow-up
39.0%
Observational data: associations, not effects.
Further findings
Demographics and comorbidities
- Female
- 55.8%
- White
- 46.7%
- Mean age, years
- 72.0
- Hypertension
- 81.2%
- Congestive HF
- 52.4%
- Hyperlipidemia
- 41.3%
- Ischemic heart disease
- 36.0%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry. Arthritis Care Res (Hoboken). Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →